First, a very happy and blessed Thanks-giving to a

Quote:

---

"BH" in a medical context is an acronym that typically stands for Behavioral Health. It is not the name of a specific patient.

Leronlimab is an investigational drug that has shown promise in clinical trials and compassionate use studies for treating metastatic triple-negative breast cancer (mTNBC).
Meaning of "BH"

In healthcare, "BH" most commonly refers to:

Behavioral Health: This encompasses mental health and substance use disorders, life stressors, and stress-related physical symptoms. The term is widely used in medical documentation, billing, and the integration of mental health services into primary care.

Patient Identifier/Acronym: It is highly unlikely that "BH" is a specific, publicly known patient's initials in the context of medical studies or news reports, as patient privacy (HIPAA in the US) is strictly protected. Patient identifiers are typically anonymized in publications.
Leronlimab for Triple-Negative Breast Cancer (TNBC)

Leronlimab is a humanized monoclonal antibody that targets the CCR5 receptor, which is found in over 95% of TNBC samples. It has been studied for its ability to reduce tumor metastasis and enhance the effect of chemotherapy and immune checkpoint inhibitors (ICIs).

Key information regarding leronlimab for TNBC includes:

Investigational Status: Leronlimab is an investigational drug and is not yet FDA-approved for the treatment of TNBC. The FDA has granted it Fast Track designation for this indication.

Clinical Trials: It has been studied in phase 1b/2 trials, compassionate use studies, and basket trials (NCT04313075, NCT03838367).

Promising Results: Studies have reported significant increases in progression-free survival (PFS) and overall survival (OS) in patients with mTNBC treated with leronlimab, sometimes in combination with standard-of-care chemotherapy.

Mechanism of Action: Leronlimab is thought to remodel the tumor immune environment by increasing PD-L1 expression on tumor cells, which may make tumors more responsive to immune checkpoint inhibitors.

In summary, while leronlimab is a subject of active research for TNBC, "Patient BH" is likely a generic or internal hospital acronym for "Behavioral Health" rather than a specific individual's name.

---